{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:18:45Z","timestamp":1782973125689,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["11730"],"award-info":[{"award-number":["11730"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06891-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:38:12Z","timestamp":1771209492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram"],"prefix":"10.1007","volume":"105","author":[{"given":"Xinyue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunzhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"3","key":"6891_CR1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95(3):316\u2013327","journal-title":"Am J Hematol"},{"key":"6891_CR2","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100992","volume":"57","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Smith MR, Nastoupil LJ (2023) Follicular lymphoma: the long and winding road leading to your cure? Blood Rev 57:100992","journal-title":"Blood Rev"},{"issue":"11","key":"6891_CR3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S et al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140(11):1229\u20131253","journal-title":"Blood"},{"issue":"9","key":"6891_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00542-z","volume":"11","author":"SH Desai","year":"2021","unstructured":"Desai SH, LaPlant B, Macon WR, King RL, Wang Y, Inwards DJ, Micallef I, Johnston PB, Porrata LF, Ansell SM et al (2021) Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer J 11(9):160","journal-title":"Blood Cancer J"},{"issue":"12","key":"6891_CR5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97(12):1638\u20131651","journal-title":"Am J Hematol"},{"issue":"31","key":"6891_CR6","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815\u20132824","journal-title":"J Clin Oncol"},{"key":"6891_CR7","doi-asserted-by":"crossref","unstructured":"Friedberg JW (2023) Update on follicular lymphoma. Hematol Oncol 2023, 41 Suppl 1(Suppl 1):43\u201347.","DOI":"10.1002\/hon.3138"},{"issue":"23","key":"6891_CR8","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"key":"6891_CR9","doi-asserted-by":"crossref","DOI":"10.1016\/j.micron.2024.103663","volume":"184","author":"R Koga","year":"2024","unstructured":"Koga R, Koide S, Tanaka H, Taguchi K, Kugler M, Yokota T, Ohshima K, Miyoshi H, Nagaishi M, Hashimoto N et al (2024) A study of criteria for grading follicular lymphoma using a cell type classifier from pathology images based on complementary-label learning. Micron 184:103663","journal-title":"Micron"},{"issue":"1","key":"6891_CR10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00428-022-03432-2","volume":"482","author":"C Laurent","year":"2023","unstructured":"Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L, Jaffe ES (2023) Follicular lymphoma and marginal zone lymphoma: how many diseases? Virchows Arch 482(1):149\u2013162","journal-title":"Virchows Arch"},{"issue":"1","key":"6891_CR11","volume":"11","author":"J Zha","year":"2023","unstructured":"Zha J, Chen Q, Ye J, Yu H, Yi S, Zheng Z, Xu W, Li Z, Ping L, He X et al (2023) Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1\u20132 follicular lymphoma: a real-world multicenter study. Biomark Res 11(1):16","journal-title":"Biomark Res"},{"issue":"9","key":"6891_CR12","first-page":"2267","volume":"108","author":"E Mulvey","year":"2023","unstructured":"Mulvey E, Leonard JP (2023) Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade? Haematologica 108(9):2267\u20132268","journal-title":"Haematologica"},{"issue":"7","key":"6891_CR13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","volume":"103","author":"H Horn","year":"2018","unstructured":"Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Tr\u00fcmper L, Spang R et al (2018) Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica 103(7):1182\u20131190","journal-title":"Haematologica"},{"issue":"1","key":"6891_CR14","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, L\u00f3pez-Guillermo A, Fitzgibbon J (2019) Follicular lymphoma. Nat Rev Dis Primers 5(1):83","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"6891_CR15","volume":"5","author":"JE Krull","year":"2024","unstructured":"Krull JE, Wenzl K, Hopper MA, Manske MK, Sarangi V, Maurer MJ, Larson MC, Mondello P, Yang Z, Novak JP et al (2024) Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments. Cell Rep Med 5(3):101443","journal-title":"Cell Rep Med"},{"issue":"3","key":"6891_CR16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","volume":"11","author":"LT Li","year":"2015","unstructured":"Li LT, Jiang G, Chen Q, Zheng JN (2015) Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 11(3):1566\u20131572","journal-title":"Mol Med Rep"},{"key":"6891_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2019.01.011","volume":"491","author":"SS Menon","year":"2019","unstructured":"Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR (2019) Ki-67 protein as a tumour proliferation marker. Clin Chim Acta 491:39\u201345","journal-title":"Clin Chim Acta"},{"key":"6891_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3165_534","author":"A Rojek","year":"2023","unstructured":"Rojek A, Venkataraman G, Fabi L, Ravisankar HV, Kline J, Riedell P, Bishop M, Pearson A, Smith S (2023) KI\u201067 proliferation patterns are predictive of early progression and inferior outcomes in grade 1\u20132 follicular lymphoma. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.3165_534","journal-title":"Hematol Oncol"},{"issue":"5","key":"6891_CR19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"27","key":"6891_CR20","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"key":"6891_CR21","volume":"13","author":"J Hu","year":"2023","unstructured":"Hu J, Gao F, Zhao J, Song W, Wang Y, Zheng Y, Wang L, Han W, Ma L, Wang J et al (2023) The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma. Front Oncol 13:1090610","journal-title":"Front Oncol"},{"issue":"11","key":"6891_CR22","first-page":"1296","volume":"88","author":"M Picardi","year":"2003","unstructured":"Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B (2003) Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin\u2019s lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 88(11):1296\u20131303","journal-title":"Haematologica"},{"issue":"33","key":"6891_CR23","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23(33):8447\u20138452","journal-title":"J Clin Oncol"},{"key":"6891_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","volume":"59","author":"A Molina","year":"2008","unstructured":"Molina A (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin\u2019s lymphoma. Annu Rev Med 59:237\u2013250","journal-title":"Annu Rev Med"},{"issue":"12","key":"6891_CR25","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732","journal-title":"Blood"},{"issue":"9","key":"6891_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW et al (2019) Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134(9):761\u2013764","journal-title":"Blood"},{"issue":"2","key":"6891_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","volume":"156","author":"BE Wahlin","year":"2012","unstructured":"Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundstr\u00f6m C, Christensson B, Sander B (2012) Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 156(2):225\u2013233","journal-title":"Br J Haematol"},{"issue":"9","key":"6891_CR28","first-page":"2444","volume":"108","author":"A Barraclough","year":"2023","unstructured":"Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Doo NW, Li EW, Gilbertson M, Shaw B et al (2023) Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica 108(9):2444\u20132453","journal-title":"Haematologica"},{"key":"6891_CR29","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood-2024-194681","volume":"144","author":"P Mondello","year":"2024","unstructured":"Mondello P, Negaard BJ, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain DA, Romancik J, Gribbin C, Haddadi S et al (2024) Subsets of follicular lymphoma (FL) 3B have divergent biological behavior and clinical outcome: results from the prospective multicenter MER and LEO cohorts. Blood 144:1629","journal-title":"Blood"},{"issue":"4","key":"6891_CR30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","volume":"23","author":"P Mondello","year":"2018","unstructured":"Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M (2018) Bendamustine plus Rituximab versus R\u2010CHOP as first\u2010line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist 23(4):454\u2013460","journal-title":"Oncologist"},{"issue":"12","key":"6891_CR31","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00277-020-04171-7","volume":"99","author":"M Pouyiourou","year":"2020","unstructured":"Pouyiourou M, Meyer A, Stroux A, Viardot A, La Ros\u00e9e P, Maschmeyer G, K\u00e4mpfe D, Kahl C, Vucinic V, Monecke A et al (2020) First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A\u2014results of a retrospective analysis. Ann Hematol 99(12):2821\u20132829","journal-title":"Ann Hematol"},{"issue":"9","key":"6891_CR32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1440-1827.2004.01678.x","volume":"54","author":"B Saito","year":"2004","unstructured":"Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, Omine M, Mitsuya T, Takimoto M, Ota H (2004) Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathol Int 54(9):667\u2013674","journal-title":"Pathol Int"},{"issue":"6","key":"6891_CR33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.21406","volume":"84","author":"A Broyde","year":"2009","unstructured":"Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O (2009) Role and prognostic significance of the Ki-67 index in non-Hodgkin\u2019s lymphoma. Am J Hematol 84(6):338\u2013343","journal-title":"Am J Hematol"},{"key":"6891_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011057","author":"H Narita","year":"2024","unstructured":"Narita H, Kuroiwa K, Kawaguchi Y, Murai S, Sasaki Y, Homma M, Kawamata N, Hayashi H, Nagao K, Okamura R et al (2024) High Ki-67 expression predicting a risk factor for the progression of disease within 24 months and microenvironment in follicular lymphoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252011057","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6891_CR35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311\u2013322","journal-title":"J Cell Physiol"},{"issue":"5","key":"6891_CR36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","volume":"32","author":"S Araf","year":"2018","unstructured":"Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S et al (2018) Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia 32(5):1261\u20131265","journal-title":"Leukemia"},{"issue":"2","key":"6891_CR37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00428-015-1864-y","volume":"468","author":"L Xerri","year":"2016","unstructured":"Xerri L, Dirnhofer S, Quintanilla-Martinez L, Sander B, Chan JKC, Campo E, Swerdlow SH, Ott G (2016) The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Arch 468(2):127\u2013139","journal-title":"Virchows Arch"},{"issue":"1","key":"6891_CR38","volume":"17","author":"R-C Li","year":"2025","unstructured":"Li R-C, Tang W, Zhang H-L, Wang X-H, Sun R, Wang N, Xu T-Y, Chen S-Y, Feng Y, Shen R et al (2025) Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement. Genome Med 17(1):131","journal-title":"Genome Med"},{"issue":"12","key":"6891_CR39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/dc.21127","volume":"37","author":"I Cozzolino","year":"2009","unstructured":"Cozzolino I, Nappa S, Picardi M, De Renzo A, Troncone G, Palombini L, Zeppa P (2009) Clonal B-cell population in a reactive lymph node in acquired immunodeficiency syndrome. Diagn Cytopathol 37(12):910\u2013914","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"6891_CR40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000448389","volume":"60","author":"I Cozzolino","year":"2016","unstructured":"Cozzolino I, Rocco M, Villani G, Picardi M (2016) Lymph node fine-needle cytology of non-Hodgkin lymphoma: diagnosis and classification by flow cytometry. Acta Cytol 60(4):302\u2013314","journal-title":"Acta Cytol"},{"issue":"1","key":"6891_CR41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1148\/radiol.14132154","volume":"272","author":"M Picardi","year":"2014","unstructured":"Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G, Pettinato G, Salvatore C, Quintarelli C, Pane F (2014) Advanced-stage Hodgkin lymphoma: US\/chest radiography for detection of relapse in patients in first complete remission\u2013a randomized trial of routine surveillance imaging procedures. Radiology 272(1):262\u2013274","journal-title":"Radiology"},{"issue":"1","key":"6891_CR42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.70277","volume":"208","author":"M Picardi","year":"2026","unstructured":"Picardi M, Vincenzi A, Pugliese N, Giordano C, Mascolo M, Vigliar E, Troncone G, Zeppa P, Pane F (2026) The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: a systematic biopsy verification. Br J Haematol 208(1):378\u2013380","journal-title":"Br J Haematol"},{"issue":"5","key":"6891_CR43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hon.3204","volume":"41","author":"M Picardi","year":"2023","unstructured":"Picardi M, Giordano C, Vigliar E, Zeppa P, Cozzolino I, Pugliese N, Della Pepa R, Esposito M, Abagnale DP, Ciriello M et al (2023) Ultrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: analysis on diagnostic efficacy and safety of 1000 front-line biopsies in a multicenter Italian study. Hematol Oncol 41(5):817\u2013827","journal-title":"Hematol Oncol"},{"issue":"5","key":"6891_CR44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W, Group ftGLGLS (2006) The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504\u20131508","journal-title":"Blood"},{"key":"6891_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15050647","author":"\u00c1 J\u00f3na","year":"2025","unstructured":"J\u00f3na \u00c1, Kiss E, Ill\u00e9s \u00c1 (2025) Prognostication of follicular lymphoma: a review of prognostic scores and factors. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics15050647","journal-title":"Diagnostics"},{"key":"6891_CR46","first-page":"413","volume":"130","author":"E Bachy","year":"2017","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas Dore B, Maucort-Boulch D, Estell J, Den Este EV, Bouabdallah R, Feldman AL, Bargay J et al (2017) Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy. Blood 130:413","journal-title":"Blood"},{"issue":"8","key":"6891_CR47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"11","key":"6891_CR48","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL et al (2020) Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21(11):1433\u20131442","journal-title":"Lancet Oncol"},{"issue":"4","key":"6891_CR49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","volume":"134","author":"E Zucca","year":"2019","unstructured":"Zucca E, Rondeau S, Vanazzi A, \u00d8stenstad B, Mey UJ, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson A-S (2019) Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 134(4):353\u2013362","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06891-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06891-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:08Z","timestamp":1776405548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06891-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6891"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06891-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (Approval No. 2025-KY-1798-001). This study is retrospective and utilized anonymized clinical data, with informed consent not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}